



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5987

Title: Immunosuppressive Therapies for Inflammatory Bowel Disease

Reviewer code: 00058695

Science editor: Cui, Xue-Mei

Date sent for review: 2013-09-30 16:25

Date reviewed: 2013-11-29 01:45

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is an exciting review of immunosuppressive therapies used for inflammatory bowel disease (IBD). The authors cover both immunomodulators as well as biologicals in a brief and balanced way. However, I have a few comments. Major comments When describing cyclosporine the authors should consider mentioning that the gap between pharmacological (therapeutic) relevant doses and toxic doses is rather narrow. Regarding certolizumab it is correct that this drug is available only in few countries, however, in the EU the drug is available after specific single case applications. When mentioning vedolizumab I suggest the authors to change reference 57 to a newer one (GEMINI1 PMID 23964932). Regarding concomitant therapy (infliximab and thiopurines) the authors mention correctly the SONIC trial. However, for ulcerative colitis the UC SUCCESS trial should be mentioned as well. The description of hepatosplenic T-cell lymphoma mentioned under the section "Combination therapy" should be moved to the section "Thiopurine analogues", as this complication from the available evidence is not linked to biologicals. Finally, I suggest the authors to summarize their findings in a conclusion. The present manuscript ends very abruptly after description of combination therapy. Thus, a "take home messages" would optimize the scientific information obtained from reading the paper. Minor comments Minor stylistic errors should be corrected throughout the text like ulcerative colitis to be capitalized in headings (U and C).



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5987

Title: Immunosuppressive Therapies for Inflammatory Bowel Disease

Reviewer code: 00227519

Science editor: Cui, Xue-Mei

Date sent for review: 2013-09-30 16:25

Date reviewed: 2013-12-05 04:36

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

I recommend revision to include a discussion of the hazards of anti-TNF agents in patients undergoing surgery for IBD. It is otherwise a good and comprehensive although superficial current review.